Company news
Therma Bright Inc. news in 2022
Therma Bright Inc.'s news releases, calls and decks from 2022, newest first.
Therma Bright Provides 2022 Year End Update
December 21, 2022
Therma Bright Invests in the Development of Novel Treatments for COVID-19, Asthma, and Chronic Obstructive Pulmonary Disease (COPD)
December 1, 2022
Therma Bright Inc. to Acquire an Exclusive License for a Patented Digital Cough Based Technology to Detect Respiratory Diseases
November 17, 2022
Therma Bright Receives New Billing Codes for Venowave Allowing for Reimbursement from Medicare, Medicaid, and Private Insurers
October 27, 2022
Therma Bright Receives Payment for Initial Venowave Sales
September 20, 2022
Therma Bright Provides Update on FDA EUA Review Process
September 12, 2022
Therma Bright Provides Progress Update on FDA EUA & Health Canada Interim Order Applications for Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
August 4, 2022
Therma Bright Submits Health Canada Application for Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test for Point-of-Care (POC)
June 23, 2022
Therma Bright Grants Stock Options
June 10, 2022
Therma Bright Provides Update on FDA EUA Application Process For AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
June 2, 2022
Therma Bright to Submit Application to Health Canada for Approval of its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
May 10, 2022
Therma Bright Ships Initial Venowave Order to US Distributor
April 28, 2022
Therma Bright Submits AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Application for U.S. Food & Drug Administration's Emergency Use Authorization (EUA)
March 29, 2022
Therma Bright Recognized In 2022 TSX Venture 50 Top Performing Stocks
February 24, 2022
Therma Bright Receives Patent for a Device for Applying a Topical Treatment from U.S. Patent & Trademark Office (USPTO)
February 23, 2022
Therma Bright Announces Closing of CAD$6 Million Private Placement with Institutional Investors
February 18, 2022
Therma Bright Announces CAD$6 Million Private Placement with Institutional Investors
February 16, 2022
Therma Bright's AcuVid(TM) U.S. Clinical Performance Study Successfully Exceeds U.S. Food & Drug Administration's Emergency Use Authorization Requirements
February 15, 2022
Therma Bright Completes U.S. Clinical Performance Study Subject Recruitment
January 31, 2022
Therma Bright Provides Update on U.S. Clinical Performance Study
January 20, 2022